Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.
Küçük Resim Yok
Tarih
2020
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Lippincott Williams & Wilkins
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
[Abstract Not Available]
Açıklama
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 29-31, 2020 -- ELECTR NETWORK
Anahtar Kelimeler
[No Keywords]
Kaynak
Journal Of Clinical Oncology
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
38
Sayı
15
